Delving into the Latest Updates on Lascufloxacin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LSFX, Lascufloxacin, Lascufloxacin hydrochloride (JAN)

+ [7]

Target

Bacterial DNA gyrase x Bacterial top IV

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication

Lung AbscessPneumoniaRespiratory Tract Infections+ [1]

Inactive Indication-

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

KYORIN Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (27 Nov 2020),

Lung AbscessPneumoniaRespiratory Tract Infections

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H24F3N3O4

InChIKeyZFIOCUITTUUVPV-MEDUHNTESA-N

CAS Registry848416-07-9

Author: Morishima, So ; Endo, Yusuke ; Oda, Machi ; Mukuda, Kengo ; Doi, Ayumu ; Inoue, Ryo ; Nishikawa, Yukari ; Chikumi, Hiroki ; Ma'arif, Athok Shofiudin ; Noma, Hisashi ; Sunada, Hiroshi ; Matsuda, Risa ; Okada, Kensaku ; Nakamoto, Masaki ; Yamasaki, Akira ; Takata, Miyako ; Kitaura, Tsuyoshi ; Takazawa, Kenji

INTRODUCTIONAntimicrobial treatment disrupts human microbiota. The effects of lascufloxacin (LSFX), a new fluoroquinolone, on human microbiota remains unknown. Therefore, in this study, we aimed to evaluate the effects of LSFX administration on the gut and salivary microbiota of healthy participants and those with pneumonia.METHODSLSFX (75 mg, once a day, orally) was administered to healthy adults (healthy group) and adult patients with pneumonia (pneumonia group), and fecal and saliva samples were collected at five time points (Days 0, 3, 7, 14, and 28). Using the collected samples, α- and β-diversity indices, as well as bacterial composition of the gut microbiota and salivary microbiota were analyzed using next-generation sequencing.RESULTSIn the healthy group, α-diversity indices of the gut and salivary microbiota were reduced and the lowest values on Day 3. For the gut microbiota, the Chao1 index (richness) recovered on Day 28, whereas the Shannon index (evenness) did not. In the salivary microbiota, the Chao1 and Shannon indices did not recover within the 28 day period. The β-diversity indices changed after LSFX administration and subsequently recovered on Day 28. After LSFX administration, the abundance of the Lachnospiraceae family decreased in the gut microbiota, and the abundance of Granulicatella, Streptococcus, Prevotella, Absconditabacteriales(SR1), and Saccharimonadales decreased in the salivary microbiota. In the pneumonia group, the α-diversity indices were lowest on Day 14 after LSFX administration.CONCLUSIONSWe elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days.

01 Jan 2025·Journal of Infection and Chemotherapy

Three cases of hospitalized Legionella pneumonia patients successfully treated with lascufloxacin

Article

Author: Nakanishi, Yosuke ; Ito, Akihiro ; Ishida, Tadashi ; Sato, Ryoju ; Kawataki, Masanori

Legionella pneumonia is one of the major causes of severe pneumonia, in which treatment delay might lead to a poor prognosis. Therefore, as far as possible, early diagnosis and treatment of Legionella pneumonia is essential. Regarding the antimicrobials for Legionella pneumonia, fluoroquinolones, such as levofloxacin, or macrolides, such as azithromycin (AZM), are recommended in Japan and other countries. Lascufloxacin (LSFX), the newest fluoroquinolone developed in Japan, has been in use in daily clinical practice since January 2020. However, there are only few reports of Legionella pneumonia cases treated with LSFX. Here, we report three cases of hospitalized Legionella pneumonia patients that were successfully treated using LSFX. All three patients were admitted to the medical ward on admission, although one patient was subsequently transferred to the ICU for mechanical ventilatory management due to worsening of the pneumonia on day 3. All patients improved and were discharged following LSFX treatment (the patient admitted to the ICU was treated using LSFX + AZM combination therapy) without any severe adverse events. LSFX might be considered to be the first antibiotic choice for Legionella pneumonia, similar to levofloxacin. However, further data regarding the treatment of Legionella pneumonia cases using LSFX are needed to evaluate its efficacy and safety.

01 Sep 2024·International Journal of Infectious Diseases

Lobar pneumonia due to human metapneumovirus: a case report

Article

Author: Kawataki, Masanori ; Koyama, Takashi ; Ito, Akihiro ; Ishida, Tadashi

Human metapneumovirus (hMPV) is a respiratory pathogen that can cause lower respiratory tract infections and pneumonia in immunocompetent adults. Pneumonia caused by hMPV is reportedly more likely to cause bronchial wall thickening and ground-glass opacity (GGO). A 44-year-old woman with no significant medical history developed fever, cough, and nausea. Computed tomography of the chest showed scattered GGOs in the right upper lobe and infiltrating shadows with air bronchograms in the left lingual and bilateral lower lobes. The patient was admitted to our hospital for further evaluation. Atypical pneumonia was suspected and lascufloxacin (LSFX) was started. Multiplex polymerase chain reaction (PCR) detected hMPV on hospital day 2 using the FilmArray Respiratory Panel 2.1. Pneumonia due to hMPV was suspected and LSFX was discontinued. The patient subsequently showed spontaneous improvement and was discharged on hospital day 6 after admission. After discharge, pneumonia continued to improve. Early detection of respiratory pathogens using multiplex PCR can help determine the appropriate treatment strategy. As hMPV can also cause lobar pneumonia, we should consider pneumonia due to hMPV in the differential diagnosis of lobar pneumonia.

1

News (Medical) associated with Lascufloxacin Hydrochloride

27 Sep 2019

·www.bioportfolio.com

Pipeline Watch: Roxadustat, Lascufloxacin Approvals In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical... Related Stories Genmab Cash Pile To Grow With Another Darzalex OK Jazz Poised To Hold Onto Strong Sleep Disorder Position Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig

100 Deals associated with Lascufloxacin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10772	Lascufloxacin Hydrochloride	J01MA	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Lung Abscess	Japan	KYORIN Pharmaceutical Co., Ltd.	27 Nov 2020
Pneumonia	Japan	KYORIN Pharmaceutical Co., Ltd.	27 Nov 2020
Respiratory Tract Infections	Japan	KYORIN Pharmaceutical Co., Ltd.	27 Nov 2020